Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

about

Immunologic approaches for the treatment of multiple myeloma.Are chronic myeloid leukemia patients ready to stop long-term treatment?CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

P2860

Q38692244-5E4CCB51-8D62-4F4F-8262-EE08446701CE Q38768659-7C3CA08C-A960-4470-B425-1112DBDDB8DD Q57191729-FE0E5F6F-0590-4FD4-A29C-FE31CEB90BBB

P2860

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

Item

http://www.wikidata.org/entity/Q42391580

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Sepantronium bromide (YM155) i ...... romal cell-induced resistance.

@en

type

Item

label

Sepantronium bromide (YM155) i ...... romal cell-induced resistance.

@en

prefLabel

Sepantronium bromide (YM155) i ...... romal cell-induced resistance.

@en

P1476

Sepantronium bromide (YM155) i ...... tromal cell-induced resistance

@en

P2093

Anton C M Martens

http://www.w3.org/2001/XMLSchema#string

Henk M Lokhorst

http://www.w3.org/2001/XMLSchema#string

Huipin Yuan

http://www.w3.org/2001/XMLSchema#string

Joost de Bruijn

http://www.w3.org/2001/XMLSchema#string

Kate Sasser

http://www.w3.org/2001/XMLSchema#string

Lisa Holthof

http://www.w3.org/2001/XMLSchema#string

Monique C Minnema

http://www.w3.org/2001/XMLSchema#string

Niels W C J van de Donk

http://www.w3.org/2001/XMLSchema#string

Parul Doshi

http://www.w3.org/2001/XMLSchema#string

Sanne J de Haart

http://www.w3.org/2001/XMLSchema#string

P2860

Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

The BCL-2 protein family: opposing activities that mediate cell death

Environment-mediated drug resistance: a major contributor to minimal residual disease.

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.

Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

P304

e339-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2015.139667

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Richard W Groen

Maarten Emmelot

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27151995

http://www.w3.org/2001/XMLSchema#string

P921

sepantronium bromide

P932

4967585

http://www.w3.org/2001/XMLSchema#string

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

about

P2860

P2860

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932